Rein Therapeutics, Inc. Common Stock RNTX Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on assets | -119.7%-41.5pp | -115.5%-40.7pp | -74.6%-24.6pp | -70.9%-30.0pp | -78.1%-47.1pp | |
| Efficiency | ||||||
| Asset turnover | 0×— | 0×— | 0×— | 0×— | 0×— | |
| Liquidity | ||||||
| Current ratio | 0.4×-1.0× | 0.7×-1.7× | 0.9×-2.4× | 0.9×-3.8× | 1.4×-1.4× | |
| Quick ratio | 0.4×-1.0× | 0.7×-1.7× | 0.9×-2.4× | 0.9×-3.8× | 1.4×-1.4× | |
| Cash ratio | 0.3×-0.9× | 0.5×-1.7× | 0.7×-2.4× | 0.7×-3.7× | 1.2×-1.4× | |
| Valuation | ||||||
| Market capitalization | $88.96M+164% | $30.49M— | $27.51M— | $32.57M— | —— | |
| Earnings yield | -59.2%+125pp | -163.6%— | -214%— | -181.6%— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Rein Therapeutics, Inc. Common Stock's ratios come from?
- Every ratio is computed from Rein Therapeutics, Inc. Common Stock's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.